IXEKIZUMAB

Brand name:

• Taltz®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Eli Lilly Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Non radiographic axial spondyloarthritis (nr-axSpA)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to listing (–)

Comment:

--

Other PBAC consideration:

--

Submission received for:

November 2021 PBAC meeting

Opportunity for consumer comment:

Open 28/07/2021 and close 22/09/2021 (see PBS Website)

PBAC meeting:

Held on 03/11/2021

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

29/04/2022

5Lodgement of required documentation:

05/05/2022

Acceptance of complete documentation:

Not Accepted

6Agreement to listing arrangements:

Has not yet commenced

7Government processes:

Has not yet commenced

8Medicine listed on the PBS:

Has not yet occurred